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and the variance-covariance matrix from the model. RESULTS:
The advantages of this new approach over the traditional
methods are two-fold: 1) The variance of Q-TWiST can be esti-
mated directly, and 2) It is possible to restrict or to compare para-
meters across different health states. CONCLUSION: Q-TWiST
represents a unique quantitative method to simultaneously eval-
uate the risks and beneﬁts of treatment on successive health
states. We present a single survival model that addresses data
censoring, covariate adjustment and variance estimation. This
new approach provides opportunities for expanded use of the Q-
TWiST method beyond the clinical trial such that application to
observational studies is possible.
Health Related Quality of Life Based Patient Reported
Outcomes: Session 1
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OBJECTIVE: The Overactive Bladder Questionnaire (OAB-q)
assesses symptom bother and health-related quality of life
(HRQL) among patients with overactive bladder (OAB) and has
been shown to be reliable, valid, and responsive. The purpose of
this analysis was to establish the instrument’s minimally impor-
tant difference (MID), which is the smallest difference in score
that patients perceive as beneﬁcial. METHODS: Data were from
four clinical trials (1 US, 3 international), totaling 3426 patients.
All trials involved 12 weeks of tolterodine treatment. Distribu-
tion-based (e.g., effect size, standard error of measurement
(SEM), and half-standard deviation) and anchor-based
approaches were used. RESULTS: The mean age of the 4 trial
samples ranged from 58.7 to 61.3 years. Patients were predom-
inantly female (65.0%) and Caucasian (87.8%). At baseline,
half-standard deviation of the OAB-q Symptom Bother subscale
ranged from 9.4 to 9.9, and SEM ranged from 7.00 to 7.28.
Half-standard deviation of the HRQL subscales (Coping,
Concern, Sleep, and Social Interaction) ranged from 9.8 to 15.6,
with SEM ranging from 6.8 to 8.3. The OAB-q subscales had
moderate to large effect sizes in all trials, with Symptom Bother
having the largest effect sizes (range = -0.61 to -1.23). Anchor-
based analyses found signiﬁcantly greater OAB-q change scores
were associated with greater patient perceived treatment beneﬁt
and satisfaction. The difference between change scores of
patients perceiving “no beneﬁt” and “little beneﬁt” ranged from
6.9 to 16.8 for all scales except Social Interaction (4.3 to 7.8),
with the majority of differences greater than 10 points (possible
subscale scores range from 0 to 100). Greater OAB-q change
scores were associated with greater improvements in micturition
diary variables. CONCLUSIONS: Multiple methodologies
provide strong justiﬁcation for recommendation of a 10-point
MID for all OAB-q subscales. This MID may be conservative for
some subscales, however a uniform MID is recommended to
facilitate instrument use and interpretation.
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OBJECTIVES: Clinical trials often include condition-speciﬁc
measures that lack the attributes required for economic evalua-
tion. This study reports on the investigation of models for esti-
mating EQ-5Dindex (a generic, utility-weighted index of health
status) from FACT-G and QLQ-C30 (two widely used cancer-
speciﬁc measures.) METHODS: As part of an observational
study in colorectal cancer FACT-G, QLQ-C30 and EQ-5D were
administered to 223 patients in an NHS hospital one week after
discharge following surgery. Alternative models for estimating
EQ-5Dindex from the items of both cancer-speciﬁc questionnaires
were evaluated. Items were treated as both continuous data or
were dichotomised. These were entered as independent variables
in a series of stepwise linear regression analyses with EQ-5Dindex
as the dependent variable. Criteria for comparing model perfor-
mance were pre-speciﬁed and included explained variance (r2),
Pearson correlation co-efﬁcient (r) and mean absolute difference.
RESULTS: More than 55% of the variance was explained by 
the model which employed continuous items and the estimated
EQ-5Dindex correlated well with actual scores (r > 0.65). Items
from FACT-G and QLQ-C30 performed equally well in this
model. Less variance was explained by the model using
dichotomised items (r2 > 0.40) and the correlation between esti-
mated and actual EQ-5Dindex was less pronounced (r > 0.45).
Items from QLQ-C30 performed better than those from FACT-
G in this model, but altering the cut-point to dichotomise the
items had an appreciable effect on explained variance. Despite
moderate to good correlation between actual and estimated EQ-
5Dindex in both models, the mean absolute difference between
these scores gave some cause for concern. CONCLUSIONS:
Despite differences in item content, both QLQ-C30 and FACT-
G generate viable estimates of EQ-5D. This is an important
ﬁnding that allows for the conversion of data from studies where
direct comparison is otherwise impossible. However, the 
technique requires further reﬁnement so as to improve its 
performance.
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OBJECTIVE: To assess the agreement between patients and
careers (Familiar-FAM, Nurse-NUR and Physician-PH) on
patients’ HRQoL and to evaluate HRQoL and burden of FAM.
METHODS: 221 patient-carrier pairs stratiﬁed by age and
gender were randomly selected from 14 dialysis units: 152
hemodialysis-69 peritoneal dialysis. Patients’ HRQoL was eval-
uated by patient and FAM, NUR and PH using EQ-5D (dimen-
sions and Visual Analogue Scale-VAS). Patients and FAM
answered the SF-36 (PCS-MCS) and Duke-UNK Functional
Social Support (FSS). FAM also answered Caregiver Burden
Interview of Zarit (ZS); PH, the co-morbidity Index of patients;
and NUR, patient’s dependence in daily activities using the
Barthel Scale (BS). RESULTS: The correlation coefﬁcients
between the VAS of the patients and their carriers were 0.42
(FAM), 0.49 (NUR) and 0.30 (PH); NUR and PH scored VAS
higher than patients (p < 0.01). The agreement (Kappa) between
EQ-5D dimension scores varied between moderate for Mobility
(0.56-FAM; 0.55-NUR; 0.47-PH) and Self-Care (0.48-FAM;
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0.50-NUR; 0.42-PH) and low or insigniﬁcant for Pain (0.32-
FAM; 0.40-NUR; 0.18-PH) and Anxiety/Depression (0.26-FAM;
0.28-NUR; 0.14-PH). The variables associated to the difference
between the VAS score of patient and carriers were studied using
lineal regression. Mean (S.D) PCS and MCS of caregivers were
48.4 (13.8) and 48.0 (11.3). Multiple regression analysis showed
that higher ZS and older patient age were associated to lower
PCS of the caregiver (R2 = 0.15; p < 0.001) and that higher ZS
and lower FSS of the caregiver, and lower MCS of the patient
were associated to lower MCS of the caregiver (R2 = 0.29; p <
0.001). Lower FSS, PCS and MCS of the caregiver and higher
age and lower PCS and MCS of the patient were associated to
higher score on ZS of caregivers (R2 = 0.49; p < 0.001). CON-
CLUSIONS: Agreement between patients and carriers was mod-
erate for “objective” dimensions of HRQOL and low for
“subjective” ones. HRQoL of FAM is slightly worse than that
of the general population. The burden of FAM depends on per-
ceived social support, patient’s age and health status of carrier
and patient.
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OBJECTIVES: To review quality of life (QoL) questionnaire use
and methods for handling missing data in published chemother-
apy studies [2000–2005 (Jan)] of non-small cell lung cancer
(NSCLC). METHODS: We conducted a detailed search of the
published literature on quality of life, NSCLC, and chemother-
apy, excluding studies with limited total sample size (<50).
Thirty-ﬁve studies covering 10 QoL questionnaires and 17
chemotherapy drugs were reviewed. RESULTS: Most studies
were conducted in Europe (primarily Italy and the U.K.), and the
average sample size was 137 patients per treatment arm (range:
16, 406). QoL questionnaires were typically self-administered at
baseline and every 3 weeks thereafter until disease progression
(roughly 2 years duration). The EORTC QLQ-C30 and EORTC
QLQ-LC13 (QLQ-LC13) questionnaires were most often used
in Europe (15 of 24 European studies); however, the FACT-L
questionnaire was commonly used in the U.S. (7 of 13 U.S.
studies). The EORTC QLQ-C30/QLQ-LC13 combination
detected signiﬁcant differences for QoL outcomes in 14 of 15
studies which reported EORTC domain scores, while the FACT-
L detected differences in 3 of 7 studies. Both questionnaires
contain similar domains, but the EORTC QLQ-C30/QLQ-LC13
includes more items on chemotherapy symptoms and FACT-L
includes items on patients’ attitude towards their cancer. Several
studies examined potential non-random bias due to missing data
resulting from death or disease progression. One study detected
conﬂicting results when including (versus excluding) missing
data from their analyses. Another study observed different QoL
results when comparing cycle-to-cycle data at similar time points
rather than study completion data using the last observation
carried forward. CONCLUSIONS: Although EORTC QLQ-
C30/QLQ-LC13 and FACT-L are both widely used, are similar
in content, and can detect differences in NSCLC patients, they
are used preferentially in Europe and the U.S, respectively. Inap-
propriate assumptions concerning the randomness of missing
data can result in biased estimates of QoL.
Cost Evaluation Studies in Interventional Cardiology
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OBJECTIVES: To inform coverage decisions regarding drug-
eluting coronary stents by assessing their cost-effectiveness for
particular high-risk patient subgroups. METHODS: The analy-
sis compared the cost-effectiveness of the two drug eluting stents
(DES) available in the UK (Cypher and Taxus) and bare-metal
stents (BMS). A review was undertaken of randomised trials
including one or both of the DES. Individual patient data were
available for some of these trials. The model parameters
extracted from the trials were further revascularisation rates,
undertaken for clinical reasons, either percutaneous interven-
tions or bypass surgery, during follow-up. Three subgroups were
considered on the basis of their higher baseline risk of repeat
revascularisation: small vessels, long lesions and diabetics; a
fourth subgroup without these risk factors was also considered.
The evidence synthesis was implemented as a Bayesian hierar-
chical logistic model. A probabilistic decision model was devel-
oped. RESULTS: Evidence from 15 trials was incorporated into
the synthesis, 5 of which supplied individual patient data. The
probability of repeat percutaneous interventions was lowest with
Cypher and highest with BMS. Both DES had lower probabili-
ties of subsequent bypass surgery than BMS, and the probability
for Taxus was slightly lower than for Cypher. Cost-effectiveness
results were sensitive to the stent prices. At current UK prices
(£908 BMS, £1300 Taxus, £1341 Cypher), Taxus is dominated
by Cypher in diabetic patients and subject to extended domi-
nance in all other subgroups. Cypher has an incremental cost per
QALY gained, compared to BMS, of £13,759, £23,086, £13,740
in patients with small vessels, long lesions and diabetes, respec-
tively. In patients with no risk factors, this increases to £35,865.
CONCLUSIONS: Given existing list prices, Cypher is likely to
be considered more cost-effective than BMS and Taxus in
patients at high baseline risk of further revascularization. This
conclusion may change following any changes in the relative
stent prices.
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OBJECTIVES: Endeavor combines the Driver stent, the drug
ABT-578 and a PC polymer into a new drug-eluting coronary
artery stent (DES) system. As results from long-term trials of
Endeavor are not yet available, economic modeling techniques
must be employed to evaluate the cost-effectiveness of this new
treatment option. The study undertook the ﬁrst assessment of
the cost-effectiveness of Endeavor DES, compared to the Driver
bare-metal stent (BMS), in the treatment of de novo lesions in
native coronary arteries. METHODS: A Markov model was
developed simulating the results of the ENDEAVOR II trial at
nine months follow-up, and extrapolating to ﬁve years using the
BENESTENT I trial. No difference was assumed between the
outcomes with the two stents after the ﬁrst year. The events
modeled were target vessel revascularisations, AMIs, cere-
